February 16, 2024
2 mins read

India rejects EU’s data exclusivity demand  

Commerce Secretary Sunil Barthwal said that there is no free trade agreement (FTA) in which India will go against the generic drug industry. ..reports Asian Lite News

India will continue to protect the interests of its generic drug firms and has rejected European Free Trade Association (EFTA) nations’ demand to keep “data exclusivity” as a part of the intellectual property (IP) chapter under a proposed bilateral trade deal, a top government official said on Thursday.

Commerce Secretary Sunil Barthwal said that there is no free trade agreement (FTA) in which India will go against the generic drug industry. EFTA comprises Iceland, Switzerland, Norway and Liechtenstein.

“They want there should be data exclusivity, but we rejected their demand. We are with our generic industry. There is no fear for the Indian generic industry (from this agreement). In fact, it is our very important objective to see that the generic drug industry flourishes,” Barthway told reporters.

For over a decade, India has been against the inclusion of data exclusivity provisions in FTAs to protect the interest of the domestic generic drug industry. Through data exclusivity, technical data generated by innovator companies get protection, which stops their competitors from getting cheaper versions of the medicine for a certain time period or till the innovator companies have ‘exclusivity rights’.

Even in the past, India’s discussions on IPR have been a contentious issue in FTA negotiations with countries such as Japan, the United Kingdom (UK) and trade blocs such as the European Union (EU).

According to international medical humanitarian organisation Doctors Without Borders/ Médecins Sans Frontières (MSF), Public Eye, and Delhi Network of Positive People, the draft leaked chapter on IP has provisions on data exclusivity, which can hamper the production of cheap, lifesaving generic medicines from India.

“This would result in generic manufacturers either needing to wait out the exclusivity period or repeat expensive clinical trials. In cases where a new medicine is patented, data exclusivity could block compulsory licences that may be granted to generic manufacturers to produce medicines at lower prices,” said a statement from MSF on Wednesday.

ALSO READ: US, UK carry out fresh strikes in Yemen

Previous Story

Indian, Chinese firms helping Russia may face EU curbs

Next Story

‘India Unfazed by England’s Bazball Talk’

Latest from -Top News

Indian-American Takes Office as Head of NIH

Born in Kolkata, India, Dr. Bhattacharya earned both his BA and MA degrees in economics from Stanford University, followed by a doctorate in medicine and a PhD in economics from the same

Trump-Putin bhai, bhai

The closer Trump and Putin get Britain, France and other Western countries which, since the end of the Second World War, have seen America as an ally, will have to rethink their

Mali embraces solar power for rural areas  

The border village of Karan and its 3,000 people used to go days without electricity. Now, enough power is available around the clock to run small video gaming centers and boost commercial
Go toTop

Don't Miss

London police under scanner over attack on Indian High Commission

The police had deployed forces in 24 buses as well

Lockheed Martin CEO calls on PM Modi in New Delhi

National Security Advisor Ajit Doval was also present at the